May 10, 2017 / 8:35 PM / 2 months ago

BRIEF-Cormedix inc qtrly loss per share $0.19

1 Min Read

May 10 (Reuters) - Cormedix Inc:

* Cormedix Inc qtrly loss per share $0.19

* Says in discussion with FDA regarding possible prospective changes to lock-it 100 trial protocol

* Says anticipate exceeding our original enrollment target of 632 patients by Q4 of 2017

* Says to pursue additional partnerships designed to further expand ex-U.S. sales of Neutrolin and begin augmenting our commercial presence in Europe

* Says expect to develop and pursue FDA clearance for potential products by 510(K) pathway

* Qtrly net sales $39,559 versus $41,427

* Says our cash used in operations in Q1 2017 was $6.8 million, compared with $6.5 million in Q4 2016 Source text: [bit.ly/2r0X5ZO]

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below